logo
The Disaster of School Closures Should Have Been Foreseen

The Disaster of School Closures Should Have Been Foreseen

The Atlantic17-04-2025

Of the many mistakes made in the COVID era, none were as glaring as prolonged school closures. The damages go beyond loss of learning, a dire consequence in its own right: Millions of families, both children and parents, still carry the scars of stress, depression, and isolation.
The closures began at a time of understandable panic, but that was only the beginning of the story. On February 25, 2020, Nancy Messonnier, the director of the CDC's National Center for Immunization and Respiratory Diseases, led a press conference to address the developing coronavirus crisis. Messonnier warned the public that, without vaccines, non-pharmaceutical interventions—things like business closures or social-distancing guidelines—would be the most important tools in the country's response. 'What is appropriate for one community seeing local transmission won't necessarily be appropriate for a community where no local transmission has occurred,' she said. The school closures that would be implemented the following month—and that endured through the end of the school year in nearly all of the roughly 13,800 school districts in the United States, in regions that had wildly different infection levels—showed this directive was not followed.
At the time of the initial closures, in mid-March, COVID was spreading quickly, but large areas in the U.S. were absent any known cases. Still, to the extent that a planned response to influenza was an appropriate universal pandemic guide, these closures were aligned with the CDC's most recent update to its pandemic playbook, released in 2017. According to that document, an initial two-week closure of schools would be sufficient to fulfill a first objective of buying authorities time to assess the severity of the pandemic. Given the news being reported of care rationing in northern-Italian hospitals, following this plan was not unreasonable—and, as part of broader stay-at-home orders, it may have had some effect on disease transmission.
'Italy spooked us,' Jennifer Nuzzo, director of the Pandemic Center at the Brown University School of Public Health, told me. 'We did not want to be Italy. The governors all saw China and Italy lock down and decided to follow their example.'
Indeed, had China not locked down, perhaps the rest of the world might not have done so either. China, governed by an authoritarian regime that rules the country with tremendous top-down power, does not share the same attitude toward personal liberties as Western democracies. And neither the CDC's pandemic playbook nor the pre-2020 consensus within the public-health field favored a lockdown of society of the breadth that we would experience. On a countrywide scale—from both an epidemiological perspective and a human-rights perspective—closing all nonessential business, closing all schools, prohibiting most social interactions and nonessential travel, and so on, was not considered feasible or wise. Because we initially lacked the ability to test, Nuzzo said, shutting schools, along with other facets of society, did make sense at first. The problem, in Nuzzo's mind, was not closing down in March; it was that there was no plan beyond that. By 'no plan,' Nuzzo was referring to two interrelated problems: all the potential harms of closures, and the challenge of unwinding interventions after they'd been implemented.
In Messonnier's press conference, she mentioned the CDC's 2017 pandemic report directly, said that school closures were part of the plan, and recognized that they were likely to be associated with unwanted consequences such as missed work and loss of income. 'I understand this whole situation may seem overwhelming and that disruption to everyday life may be severe,' she advised. 'You should think about what you would do for child care if schools or day cares close.' There was no mention of how the government might aid families during school closures, or, for example, about what a single parent with a job as a cashier in a grocery store and a 4-year-old at home was supposed to do. Rather, in just one line amid a lengthy speech, people were told to simply 'think about' it. To government officials and many others at the time, this was a regrettable but entirely reasonable approach—a presumed temporary loss of wages and child-care issues were lower-order concerns compared with the coming onslaught of a pandemic.
Yet what was positioned as a secondary issue—a mere abstraction, warranting just a brief mention—led to catastrophic consequences for millions of children, and their families. A year later, my kids, along with tens of millions of other students, were still trudging through remote learning, either as their exclusive form of schooling or through so-called hybrid schedules during which they could attend classes only part time. (Meanwhile, bars, restaurants, and all manner of other businesses had long since reopened, as had many private schools.) Teachers in much of the country had been prioritized for vaccines—making them eligible for protection before some other, more vulnerable populations—yet schools in half the country still weren't open full time, and in many places weren't open at all.
While federal public-health officials made recommendations regarding schools, the actual closures were carried out at the state and local levels, in response to misplaced public fears and aggressive campaigning by teachers' unions. Randi Weingarten, the high-profile head of the American Federation of Teachers, said in a February 8, 2021, New York Times article that she hoped things would be 'as normal as possible' by the following fall. Class-action lawsuits in multiple states had been filed on behalf of children with special needs on the claim that the conditions of IDEA—a federal law that requires certain services (such as physical and occupational therapy, supplemental aids and equipment, etc.) for children with disabilities—were not being met in remote-learning models.
Opinion pieces with titles such as 'Remote School Is a Nightmare. Few in Power Care,' had been appearing in major news outlets since the previous summer. Working parents, especially mothers, were dropping out of the workforce in staggering numbers because of child-care obligations during the pandemic. An analysis by the U.S. Chamber of Commerce found that nearly 60 percent of parents who had left the workforce had done so for this reason. The psychic toll on parents and children was never—and can never be—calculated. It won't show up in statistics, but it was real for millions of families. And millions of children, especially those without resources for tutors or parents to oversee them during the day, were losing ground with their academics. Worse, they were suffering from isolation, frustration, and, for an increasing number of them, depression from spending their days alone in front of an electronic screen. Untold numbers of other children became 'lost,' having dropped out of school entirely. Those in power who advocated for school closures were not adequately prepared for these consequences, which were still pervasive a full year into the pandemic.
But they should have been.
The damaging effects of school interruptions were not unforeseen. They were explicitly warned about in the academic literature. Exhibit A is a 2006 paper called 'Disease Mitigation Measures in the Control of Pandemic Influenza,' in the journal Biosecurity and Bioterrorism, written by Nuzzo; her mentor (and global eminence on disease-outbreak policies), D. A. Henderson; and two others. 'There is simply too little experience to predict how a 21st century population would respond, for example, to the closure of all schools for periods of many weeks to months,' these authors wrote. 'Disease mitigation measures, however well intentioned, have potential social, economic, and political consequences that need to be fully considered by political leaders as well as health officials. Closing schools is an example.'
The authors went on to warn that closures would force some parents to stay home from work, and they worried about certain segments of society being forced to bear an unfair share of the burden from transmission-control policies. They wrote:
No model, no matter how accurate its epidemiologic assumptions, can illuminate or predict the secondary and tertiary effects of particular disease mitigation measures … If particular measures are applied for many weeks or months, the long-term or cumulative second- and third-order effects could be devastating.
Nearly a decade and a half before the pandemic—in a stark rebuke to the approach championed by the CDC, White House Coronavirus Response Task Force coordinator Deborah Birx, and other powers that be—the paper had called out the major harms that would come to afflict many families in our country as a result of school closures. Yet, from the spring of 2020, health officials who directed our pandemic response ignored many of the consequences they must have known to expect. Or, at the very least, they failed to provide adequate information about them to the public. The officials had opened a bottle of medicine while disregarding the skull and crossbones on the warning label.
And the portents were not just in Henderson's and Nuzzo's paper. A 2011 paper by researchers from Georgetown assessed the decision making behind—and the consequences from—several hundred brief school closures enacted during the 2009 H1N1 pandemic. The authors noted that the child-care costs to families were substantial, and that hardships from closures were inequitable. 'Officials considering closure must weigh not only the total amount of disruption but also the extent to which social costs will be disproportionately borne by certain segments of society,' the authors wrote. Even the CDC playbooks themselves warn of some of these issues. Both the 2007 original and the updated 2017 report cautioned that school closures could lead to the secondary consequence of missed work and loss of income for parents who needed to stay home to take care of their school-age children. This effect, the latter report noted, would be most harmful for lower-income families, who were also hit hardest by COVID in the first place. With prescience, and comic understatement, the authors noted that school closures would be among the 'most controversial' elements of the plan.
Meanwhile, the second of Nuzzo's points—that unwinding interventions is often incredibly difficult, and there must be a plan on how to do so—was also a well-established phenomenon. Just as public-health experts are biased toward intervention, they, along with the public, are also biased toward keeping interventions in place. This is a known phenomenon within the literature of implementation science, a field of study focused on methods to promote the adoption of evidence-based practices in medicine and public health. Westyn Branch-Elliman, an infectious-diseases physician at UCLA School of Medicine with an expertise in implementation science, told me that de-implementation is generally much harder than implementation. 'People tend to err on the side of intervening, and there is often considerable anxiety in removing something you believe has provided safety,' she said.
There also is a sense of inertia and leaving well enough alone. It's not unlike legislation—oftentimes repealing a law, even an unpopular one, poses bigger challenges than whatever barriers existed to getting it passed. Although the initial school closures may have been justifiable (even if off-script in many locations), there was no plan on when and how to reopen. Officials repeated a refrain that schools should open when it was 'safe.' But 'safe' was either pegged to unreachable or arbitrary benchmarks or, more often, not defined. This meant there would be limited recourse against a public that had been led to believe this intervention was a net benefit, even long after evidence showed otherwise. The lack of an exit plan—or an 'off-ramp,' as many health professionals would later term it—would prove disastrous for tens of millions of children in locations where social and political pressures prevented a reversal of the closures.
Without sufficient acknowledgment of the harms of school closures, or adequate planning for unwinding this intervention, officials showed that their decisions to close were simply reactive rather than carefully considered. The decision makers set a radical project in motion with no plan on how to stop it. In effect, officials steered a car off the road, threw a cinder block on the accelerator, then jumped out of the vehicle with passengers still in the back. No one was in the front or even knew how to unstick the pedal.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US FDA approves Merck's RSV antibody for infants
US FDA approves Merck's RSV antibody for infants

Yahoo

timean hour ago

  • Yahoo

US FDA approves Merck's RSV antibody for infants

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available in the country for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. The approval was based on results from a late-stage trial in which Enflonsia had a comparable safety profile to Swedish Orphan Biovitrum's Synagis, a monthly injection. Merck said that Enflonsia is the first and only RSV preventive option administered to infants using the same dose regardless of weight, and it told Reuters the drug will be priced at $556 per dose. Jefferies analyst Akash Tewari said last year that this is beneficial since physicians have to forecast an infant's potential weight during RSV season with Beyfortus, which makes dose ordering and inventory more complex. In the U.S., an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV each year, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.

3 Healthcare Stocks Skating on Thin Ice
3 Healthcare Stocks Skating on Thin Ice

Yahoo

timean hour ago

  • Yahoo

3 Healthcare Stocks Skating on Thin Ice

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio

US FDA approves Merck's RSV antibody for infants
US FDA approves Merck's RSV antibody for infants

Yahoo

timean hour ago

  • Yahoo

US FDA approves Merck's RSV antibody for infants

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. Each year in the United States, an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store